By Dr Karan Wadhwa, consultant urological surgeon at Phoenix Hospital Group and clinical director at CHAPS
In the UK, around one in five men dies before the age of 65, many from conditions that are preventable or far more treatable when detected early.
Prostate cancer is central to that challenge. It is the most common cancer in men in the UK, responsible for around 65,000 diagnoses and 12,000 deaths each year- yet there is still no national screening programme.
According to Prostate Cancer UK, 64,425 men were diagnosed with prostate cancer in 2022, surpassing the number of women diagnosed with breast cancer. This rise reflects, in part, a post-pandemic recovery in testing and diagnosis.
Despite this growing awareness, screening remains controversial. The UK National Screening Committee is expected to publish its final recommendation on a national screening programme shortly, having previously advised against routine population screening for most men.
For a disease of this scale, the absence of a structured screening pathway raises important clinical and public health questions.
At the same time, there is an increasing need to ensure men have access to accurate, timely diagnostics. At Phoenix Hospital Group, we are working with specialist urology expertise to provide rapid access to gold-standard prostate cancer diagnostics, helping to support earlier detection and more informed decision-making.
The silent nature of prostate cancer
Prostate cancer often develops without obvious symptoms in its early stages. Many men only become aware of a problem once the disease has progressed, when treatment becomes more complex and outcomes are less favourable.
This is why early detection remains such an important goal.
Historically, concerns around screening have centred on the limitations of the PSA blood test, particularly the risks of overdiagnosis and overtreatment. However, the scientific landscape is evolving.
New long-term data from the European Randomised Study of Screening for Prostate Cancer, presented at the European Association of Urology Congress in London, suggests screening may save more lives than previously estimated.
Long-term follow-up indicates that approximately one prostate cancer death may be prevented for every six cancers detected through screening, although this reflects decades of follow-up and depends on how screening is implemented.
Earlier estimates suggested one life saved for every 27 men diagnosed.
A new generation of screening strategies
Prostate cancer screening is no longer reliant on a single PSA test. Modern diagnostic pathways increasingly combine multiple tools to improve accuracy and reduce unnecessary procedures, including:
- PSA blood testing
- Genetic risk assessment
- High-resolution MRI imaging
- Risk-stratified screening pathways
The landmark TRANSFORM trial is currently investigating how these approaches can be combined most effectively, with men being invited to participate through NHS and research pathways.
Alongside this, international experts are increasingly highlighting the role of MRI as a frontline screening tool.
A panel of 21 urologists, radiologists and pathologists from Europe and the US recently issued an expert consensus recommending that men over 50 should be offered rapid MRI scans lasting under 15 minutes to detect prostate cancer earlier.
The recommendations, developed by researchers at Imperial College London and presented at the European Association of Urology Congress, suggest that targeted MRI scans could identify clinically significant tumours while reducing unnecessary biopsies and overdiagnosis.
Together, these developments point to a broader shift towards smarter, more targeted screening strategies.
Moving from reactive to proactive healthcare
As clinicians, we regularly meet men who say they wish their cancer had been detected earlier.
Too often, men remain unaware of their risk or delay seeking advice, particularly as prostate cancer can develop silently. Improving awareness and access to appropriate diagnostic pathways is therefore essential.
At CHAPS, we continue to advocate for evidence-based approaches that could reduce the number of men dying from prostate cancer. The aim is not simply to diagnose more cancers, but to identify clinically significant cancers early enough to save lives.
Improving access to advanced diagnostics
Alongside research and policy discussions, improving access to high-quality diagnostics is a critical part of the solution.
At Phoenix Hospital Group, we are expanding access to advanced prostate MRI screening, combining specialist urological assessment with high-resolution imaging to provide faster, more accurate answers for patients.
Modern MRI technology can identify clinically significant cancers with far greater precision, allowing clinicians to distinguish between cancers that require treatment and those that can be safely monitored. This supports a more personalised and less invasive approach to care.
A turning point for men’s health
The conversation around prostate cancer screening is evolving.
With stronger evidence, improved diagnostic tools and landmark trials such as TRANSFORM underway, the UK may be approaching a pivotal moment in how prostate cancer is detected.
The challenge now is not whether screening should evolve, but how we implement smarter, safer and more effective strategies.
Because when it comes to prostate cancer, earlier detection does more than improve outcomes – it saves lives.
